SoundDT
16 Nov 2018
eCOA contract I found this interview regarding the recent significant contract win for Cambridge Cognition.
Ripley94
10 Jan 2018
Re: Nigel Wray has 20% Never heard of this share, until i read Marksman posted he sold today on a profit warning .Thread tapped as this post gives me a quick idea of what they do .
Stellaria media
19 Apr 2017
Target price? I see that a target price of 130p has been posted. It appears that we are getting there. Suspect that there will be profit taking to bring the price down, but overall the progress and upswing is pleasing to see.
Sambram
22 Sep 2016
interim results out this morning finnCap update out this morning: "2016 interim results validate management’s decision to focus on marketing and commercialisation with evidence of the core product suite beginning to gain market traction. Two new distribution deals, a JV for wearable devices and the first contract win for CANTAB Recruit indicate that COG is beginning to be noticed for the right reasons. We make no changes to our forecasts at this time but have upgraded our target price to 115p, reflecting both the recognition of new product adoption and delivery on commercialisation strategy as well as peer group comparisons. Catalysts for intrinsic/market value include further contract wins as well as the potential for CANTAB mobile gaining FDA approval in 2017."
Chip_Scashtin
17 Aug 2016
Easy come easy go Or the other way round. I was just thinking of leaving a comment saying this one seems to be bubbling up a bit, when wham! Hang on to your hats maybe we are being bought by the Japanese!
Simbrad
27 Jun 2016
"The specialist developer and distributor of computerised neuropsychological tests has announced its second distribution agreement for third party products this month. The deal announced last week confers to the Company the sole rights to market the MANUS Parkinson's Pen, a sensor pen for diagnosis and monitoring of neuromotor impairments, in academic research, pharmaceutical clinical trials and occupational health markets. The device is a CE marked Class I medical device." Hybridan note out this morning on research tree
Simbrad
22 Jun 2016
finnCap note out this morning on research tree "Cambridge Cognition announced that it has signed an agreement with MANUS Neurodynamica, a UK-based healthcare technology company, to sell the MANUS Parkinson’s Pen for the diagnosis and monitoring of neuromotor impairments such as Parkinson’s in academic research, pharmaceutical clinical trials and occupational health markets."
Simbr
02 Jun 2016
AnthroTronix agreement Cambridge Cognition announced that it has signed an agreement with AnthroTronix in the US to sell DANA to European military organisations and occupational health providers in addition to its core global academic research and pharmaceutical clinical trials markets. The distribution agreement is illustrative of how the company intends to exploit is existing strong sales channels into the pharma clinical trials markets, by pushing more innovative content through them. We make... finnCap's note from this morning, it's on researchtree
Simbrad
02 Jun 2016
finnCap's note out this morning: "Cambridge Cognition announced that it has signed an agreement with AnthroTronix in the US to sell DANA to European military organisations and occupational health providers in addition to its core global academic research and pharmaceutical clinical trials markets. The distribution agreement is illustrative of how the company intends to exploit is existing strong sales channels into the pharma clinical trials markets, by pushing more innovative content through them. We make..." on Research Tree
Stellaria media
06 May 2016
Faith. Good to see that directors have faith even if the market does not.
BurglarBill
18 Jan 2016
Re: thoughts? From the interims "and expects to end the year with three new major pharmaceutical clinical trial contracts totalling US$4.5m"Could be coincidence but IXICO "the brain health company, today announces that it has recently been awarded four new contracts with leading pharmaceutical companies and a specialist biotechnology company, with a combined value of over £3.0m...for global clinical trials of novel drugs for Alzheimer's disease"
Stellaria media
12 Jan 2016
thoughts? sudden drop and continuing falls. It was doing reasonably well. I suppose it is the nature of the beast and the jungle that is "stocks and shares" Not much news out there to guide us. can any one shed light on the matter?
coldascheese
10 Sep 2015
Results Doesn't seem to be making much headway here and I was expecting a small profit-very dissapointing, looks like thats a few years away so I am out
coldascheese
25 Mar 2015
Re: info Sorry wrong info-here is the right one[link]
coldascheese
25 Mar 2015
info Interesting article on COG[link]
